T1673

Acamprosate calcium (Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems, used for treating alcohol dependence.

Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment.

Rentiapril racemate (SA-446 racemate) is the racemic form of Rentiapril, exhibiting anti-inflammatory properties and potential applications in glaucoma research.

RG-12525(NID 525) is an orally available, selective and competitive leukotriene D (LTD) antagonist that inhibits LTC4, LTD4 and LTE4-induced contraction of guinea pig thin-walled bands, with IC50 values of 2.6 nM, 2.5 nM, and 7 nM, respectively.RG-12525 inhibits CYP3A4, with a Ki value of 0.5 µM. RG-12525 is a novel and potent PPAR-γ agonist (IC50 value of about 60 nM) with species specificity for the study of asthma.

Reproxalap (NS-2) covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal. Reproxalap is a reactive aldehyde species sequestering agent for the treatment of the dry eye.

Resolvin E1 (RvE1) is an endogenous lipid mediator derived from the omega-3 fatty acid eicosapentaenoic acid (EPA). It exhibits anti-inflammatory properties, activates inflammation resolution, and promotes phagocytic clearance. It prevents 2,4,6-trinitrobenzenesulfonic acid-induced colitis and improves erythrocytosis and severe aplastic anaemia (SAA).

RET-IN-1 is a RET kinase inhibitor with IC50 values of 1 nM for RET (WT), 7 nM for RET (V804M), and 101 nM for RET (G810R).

Retosiban is an effective and selective oxytocin antagonist (Ki: 0.65 nM).

Revexepride is a highly selective agonist of the 5-HT4 receptor and a potential inducer of CYP3A4 enzyme. Revexepride is used for the treatment of gastroesophageal reflux disease.

RF9 is an effective and selective antagonist of the Neuropeptide FF receptor (Kis: 58±5 and 75±9 nM for hNPFF1R and hNPFF2R, respectively).